You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CISATRACURIUM BESYLATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Cisatracurium Besylate, and what generic alternatives are available?

Cisatracurium Besylate is a drug marketed by Accord Hlthcare, Caplin, Eugia Pharma, Fresenius Kabi Usa, Hengrui Pharma, Hikma, Hospira, Meitheal, Piramal Critical, Piramal Hlthcare Uk, Sagent Pharms Inc, Sandoz Inc, Somerset, Zydus Pharms, and Somerset Theraps Llc. and is included in twenty-seven NDAs.

The generic ingredient in CISATRACURIUM BESYLATE is cisatracurium besylate. There are nine drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cisatracurium Besylate

A generic version of CISATRACURIUM BESYLATE was approved as cisatracurium besylate by SANDOZ INC on February 3rd, 2012.

  Try a Trial

Drug patent expirations by year for CISATRACURIUM BESYLATE
Drug Prices for CISATRACURIUM BESYLATE

See drug prices for CISATRACURIUM BESYLATE

Recent Clinical Trials for CISATRACURIUM BESYLATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Second Affiliated Hospital of Nanchang UniversityPhase 4
Yichang Humanwell Pharmaceutical Co.,LtdPhase 4
Second Affiliated Hospital of Nanchang UniversityN/A

See all CISATRACURIUM BESYLATE clinical trials

Pharmacology for CISATRACURIUM BESYLATE
Paragraph IV (Patent) Challenges for CISATRACURIUM BESYLATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NIMBEX PRESERVATIVE FREE Injection cisatracurium besylate 2 mg/mL, 10 mL vial 020551 1 2009-08-12
NIMBEX PRESERVATIVE FREE Injection cisatracurium besylate 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial 020551 1 2009-08-04

US Patents and Regulatory Information for CISATRACURIUM BESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eugia Pharma CISATRACURIUM BESYLATE PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 209665-001 Oct 27, 2020 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Zydus Pharms CISATRACURIUM BESYLATE cisatracurium besylate INJECTABLE;INJECTION 213527-001 Aug 31, 2020 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Fresenius Kabi Usa CISATRACURIUM BESYLATE PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 203182-001 Feb 26, 2015 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Zydus Pharms CISATRACURIUM BESYLATE cisatracurium besylate INJECTABLE;INJECTION 212171-002 Nov 4, 2019 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Accord Hlthcare CISATRACURIUM BESYLATE cisatracurium besylate INJECTABLE;INJECTION 205873-001 Jun 16, 2017 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Piramal Critical CISATRACURIUM BESYLATE cisatracurium besylate INJECTABLE;INJECTION 215516-002 May 24, 2022 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.